Shots:

• The companies enter into a license agreement for the Preserflo MicroShunt superseding the previous collaboration between the two parties
• Glaukos get exclusive commercialization rights for the MicroShunt in the US- Australia- New Zealand- Canada- Brazil- Mexico and the remainder of Latin America and gain full control over all development activities for the MicroShunt in the same territories- including development and regulatory activities in the US
• Santen will continue to manufacture & supply the MicroShunt for the Glaukos territories and lead development & commercialization activities elsewhere. In Jun’2020- Santen has submitted PMA to the US FDA

  Ref: BUSINESS WIRE | Image: Glaukos